PE64498A1 - Metodo para tratar la inflamacion - Google Patents

Metodo para tratar la inflamacion

Info

Publication number
PE64498A1
PE64498A1 PE1997000324A PE00032497A PE64498A1 PE 64498 A1 PE64498 A1 PE 64498A1 PE 1997000324 A PE1997000324 A PE 1997000324A PE 00032497 A PE00032497 A PE 00032497A PE 64498 A1 PE64498 A1 PE 64498A1
Authority
PE
Peru
Prior art keywords
steroids
combination
treating inflammation
damage
treatment
Prior art date
Application number
PE1997000324A
Other languages
English (en)
Inventor
Sidney R Smith
Satwant R Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE64498A1 publication Critical patent/PE64498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

CARACTERIZADO PORQUE COMPRENDE ADMINISTRAR UNA COMBINACION DE INTERLEUCINA-10 (IL-10) Y POR LO MENOS UN ESTEROIDE TAL COMO PREDNISONA, DEXAMETASONA, FLUTICASONA Y BETAMETASONA, EN DONDE DICHA IL-10 QUE PUEDE SER IL-10 HUMANA, RECOMBINANTE HUMMANA O VIRAL ES UNA PROTEINA CARACTERIZADA POR UNA SECUENCIA DE AMINOACIDOS DE IL-10 COMPLETA (POR EJEMPLO, CARECIENDO DE SECUENCIA SECRETORIA GUIA), O POR UNA ACTIVIDAD BIOLOGICA COMUN A LA IL-10 NATURAL. LA ACTIVIDAD SINERGICA DE TAL COMBINACION PROVEE UN TRATAMIENTO MAS CORTO Y ELIMINA O REDUCE LOS EFECTOS DE LOS ESTEROIDES TALES COMO EL DANO HEPATICO, DANO RENAL Y LA SUSCEPTIBILIDAD INCREMENTADA A LA INFECCION AL USAR CANTIDADES MENORES DE ESTEROIDES EN EL TRATAMIENTO DEL SHOCK SEPTICO O DE ENFERMEDADES AUTO-INMUNES QUE EXHIBEN INFLAMACION COMO SINTOMA
PE1997000324A 1996-05-03 1997-04-29 Metodo para tratar la inflamacion PE64498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/642,816 US5753218A (en) 1996-05-03 1996-05-03 Method for treating inflammation

Publications (1)

Publication Number Publication Date
PE64498A1 true PE64498A1 (es) 1998-10-29

Family

ID=24578143

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000324A PE64498A1 (es) 1996-05-03 1997-04-29 Metodo para tratar la inflamacion

Country Status (15)

Country Link
US (1) US5753218A (es)
EP (1) EP0906118A1 (es)
JP (1) JP2000509715A (es)
KR (1) KR20000010706A (es)
AR (1) AR006932A1 (es)
AU (1) AU718857B2 (es)
BR (1) BR9708908A (es)
CA (1) CA2253312A1 (es)
HU (1) HUP9903144A3 (es)
ID (1) ID17194A (es)
IL (1) IL126759A0 (es)
NZ (1) NZ332464A (es)
PE (1) PE64498A1 (es)
WO (1) WO1997041882A1 (es)
ZA (1) ZA973707B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5800268A (en) 1995-10-20 1998-09-01 Molnick; Melvin Method of participating in a live casino game from a remote location
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU4341300A (en) * 1999-04-13 2000-11-14 Schering Corporation Novel uses of mammalian ox2 protein and related reagents
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU6376700A (en) * 1999-07-28 2001-02-19 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
WO2001008717A1 (en) * 1999-08-03 2001-02-08 Smith & Nephew, Inc. Controlled release implantable devices
US20040063685A1 (en) * 2000-12-08 2004-04-01 Juji Ilzawa Combination Drugs
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030103941A1 (en) * 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
AU2002352925A1 (en) * 2001-11-28 2003-06-10 Schering Corporation Method for treating and preventing pancreatitis
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US9511076B2 (en) * 2008-05-30 2016-12-06 Clarion Research Group Formulations and methods for recovery from dental surgery
US20120195938A1 (en) * 2007-05-30 2012-08-02 James Louis Rutkowski Formulations and methods for recovery from dental surgery
EP2654756A1 (en) * 2010-12-22 2013-10-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound having antibacterial activity
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
KR102624174B1 (ko) * 2020-09-18 2024-01-23 주식회사 아미코젠파마 수가용화된 담즙산을 포함하는 패혈증, 급성 폐손상 질환, 또는 급성 호흡곤란증후군의 예방 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
EP0502080A4 (en) * 1989-11-21 1993-02-10 The University Of Melbourne Anti-inflammatory compositions and methods
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US5368854A (en) * 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JPH11510185A (ja) * 1995-08-07 1999-09-07 シェーリング コーポレイション インターロイキン−１０を用いた眼の炎症性状態の処置

Also Published As

Publication number Publication date
BR9708908A (pt) 1999-08-03
HUP9903144A2 (hu) 2000-03-28
JP2000509715A (ja) 2000-08-02
KR20000010706A (ko) 2000-02-25
EP0906118A1 (en) 1999-04-07
HUP9903144A3 (en) 2000-11-28
ZA973707B (en) 1997-10-29
IL126759A0 (en) 1999-08-17
AR006932A1 (es) 1999-09-29
NZ332464A (en) 2000-07-28
ID17194A (id) 1997-12-11
AU718857B2 (en) 2000-04-20
AU2808997A (en) 1997-11-26
WO1997041882A1 (en) 1997-11-13
CA2253312A1 (en) 1997-11-13
US5753218A (en) 1998-05-19

Similar Documents

Publication Publication Date Title
PE64498A1 (es) Metodo para tratar la inflamacion
Buring On the origin of cells in heterotopic bone formation
Cline et al. Effects of ultraviolet radiation on the leaves of higher plants
DE69231486T2 (de) Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
DK545584D0 (da) Enzym-resistente immonumodulatoriske peptider
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
RU93058524A (ru) Системы с регулируемым высвобождением и низкими дозами андрогенов, способ их получения и способ лечения с помощью этих систем
DE59004337D1 (de) Sterole, deren fettsäureester und glucoside; verfahren zu ihrer herstellung; spontan dispergierbare mittel mit diesen verbindungen, sowie ihre verwendung zur behandlung von tumoren.
ES2053413T1 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ES2032276T3 (es) Metodo para el tratamiento de plasma y productos derivados del mismo.
Ketchum et al. The degradation of mature collagen: a laboratory study
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
ATE50583T1 (de) Gallensaeure-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die sie enthalten.
ATE459355T1 (de) Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung
ROSENFELD et al. Irradiation and adrenal steroidogenesis: steroid transformations by irradiated isolated perfused calf adrenals
Guzek Effect of adrenocorticotrophic hormone and cortisone on the uptake of tritiated thymidine by regenerating liver tissue in the white rat
Maor et al. Concerning the mechanism of the increased RNase activity in lymphatic cells following whole-body irradiation
ATE26710T1 (de) Substituierte tert.-butanol-derivate, verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel.
DE69933581D1 (de) Verwendung von humanem wachstumshormon zur vermehrung der anzahl zirkulierender cd34+ zellen, zur wiederherstellung des hämapoietischen- und des immunsystems nach myeloablativer oder antiblastischer therapie, bei transplantation oder re-infusion
ATE306946T1 (de) Transfektionssystem
Tribukait Hämoglobinmenge und Blutvolumen der Ratte und ihre Beziehung zum Körpergewicht
Hornung An overview of formal methodological requirements for controlled clinical trials
Martinkaitytė et al. Stem Cell Therapy in Multiple Sclerosis: Current Progress and Future Prospects.
Kihlman Cytological effects of phenylnitrosamines—III. The effect on X-ray sensitivity at low oxygen tensions
JPS6410335A (en) System for shortening compiling time

Legal Events

Date Code Title Description
FD Application declared void or lapsed